PPMD Community

All Blog Posts Tagged 'Staff' (652)


Staff
Duchenne Research Update: October 2016

When I first joined the Duchenne community in 2009 at Children’s National Medical Center, I remember thinking that I was walking into a critical juncture in Duchenne history. There were three compounds in the clinic (drisapersen, ataluren, and eteplirsen aka Exondys…

Continue

Added by Abby Bronson on October 18, 2016 at 1:00pm — No Comments


Staff
DuchenneConnect Twitter Chat on Thursday, October 20 at 1PM EST

Join us for our first DuchenneConnect Twitter chat on Thursday, Oct 20, 2016 from 1-2:00 PM EST. We will be using the hashtag #DuchenneConnectTC.



Our first chat will cover the…

Continue

Added by Ann Lucas on October 17, 2016 at 11:30am — No Comments


Staff
PTC Therapeutics Provides Regulatory Update on Translarna™

PPMD is disappointed to learn that the FDA denied PTC Therapeutics' first appeal of the refuse to file letter issued in February. As we understand it, this is a process and may involve additional appeals. PPMD will be…

Continue

Added by PPMD on October 17, 2016 at 10:24am — No Comments


Staff
PPMD Demands Anthem Reconsider Coverage of Approved Drug

It is hard to imagine anything worse than receiving the diagnosis of Duchenne. The dates and odysseys that brought us into this community differ, but the fervor we share to slow and stop the progression of this disease as it marches through our children is unparalleled in any…

Continue

Added by Pat Furlong on October 14, 2016 at 12:02pm — No Comments


Staff
Connect with PPMD in 2017!

Can you believe 2017 is just around the corner? It will be here before you know it and PPMD is busy putting together an exciting list of events that will continue to connect and inform our Duchenne community. It’s already a packed new year!

 

Check out where your PPMD family plans to be in 2017 and mark your calendars!…

Upcoming Events

Continue

Added by PPMD on October 14, 2016 at 9:30am — No Comments


Staff
ABLE Accounts: Improvements Moving Through Congress & Determining Which State’s Program is Best for You?

With the initiation of 4 states ABLE programs already begun and Oregon having just anounced that their program will launch in December, any qualified individual (meaning most families with Duchenne) can open their accounts in 2016, if interested. We have previously shared information…

Continue

Added by Annie Kennedy on October 13, 2016 at 8:37pm — No Comments


Staff
PPMD Awards $239,000 Research Grant to Dr. Terence Partridge of Children’s National Medical Center

Parent Project Muscular Dystrophy (PPMD) has awarded a $239,000 grant to Dr. Terence Partridge, Professor of Systematic Integrative Biology, Research Center for Genetic Medicine at Children's National Medical Center. This grant will help Dr. Partridge and his team continue their work in…

Continue

Added by PPMD on October 13, 2016 at 11:31am — No Comments


Staff
Calling All Adults with Duchenne/Becker – Join the 2017 PPMD Adult Advisory Committee!

Ever wished you could change the world – or at least your piece of it? Been looking for a way to engage a bit more? Have personal experience that you’d like to see be better reflected in national policy and program efforts?



PPMD is seeking adult members of our Duchenne/Becker…

Continue

Added by Annie Kennedy on October 12, 2016 at 11:30am — No Comments


Staff
[Webinar Takeaways] Preparing for Access to Approved Therapies

Last week, PPMD began a webinar series on access – an exciting new chapter for our Duchenne community. But we are just at the beginning of this chapter and there is lots to explore.



We knew this day was coming –…

Continue

Added by Annie Kennedy on October 11, 2016 at 3:00pm — No Comments


Staff
Anthem and Exondys 51 (Eteplirsen)

PPMD is deeply troubled to learn that health insurer Anthem will not be covering Exondys 51, stating the following position:

“The use of eteplirsen is considered investigational and not medically necessary for all indications, including but not limited to the treatment of Duchenne muscular dystrophy.”

This is not an…

Continue

Added by PPMD on October 7, 2016 at 2:30pm — No Comments


Staff
PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients

PTC Therapeutics, Inc. today announced new data supporting the potential benefit of ataluren in preserving lung function in non-ambulatory people with nonsense mutation Duchenne. PPMD continues to urge the FDA to provide PTC with a full review and advisory committee meeting.…

Continue

Added by PPMD on October 6, 2016 at 9:15am — No Comments


Staff
PPMD's DuchenneConnect Team Presents at Annual Genetic Conference



Last week, Ann Lucas and I had the honor of presenting an Educational Breakout Session focused on Duchenne at the National Society of Genetic Counselors (NSGC) Annual Education Conference in Seattle. Lauren Morgenroth from TRiNDS also presented during the…

Continue

Added by Ann Martin on October 5, 2016 at 1:00pm — No Comments


Staff
Catabasis Completes Target Enrollment for Part B of the MoveDMD® Trial, a Phase 2 Trial of Edasalonexent (CAT-1004) for the Potential Treatment of Duchenne Muscular Dystrophy

Catabasis announced that target enrollment of 30 patients has been reached for Part B of the MoveDMD trial, a 12-week trial to assess the safety and efficacy of edasalonexent (CAT-1004) in Duchenne. Edasalonexent is an oral small molecule that the company believes has the potential to be a…

Continue

Added by PPMD on October 4, 2016 at 11:00am — No Comments


Staff
New Research Validates Translarna's™ (ataluren) Mechanism of Action to Promote Readthrough of Nonsense Mutations and Produce Full-length Functional Protein

PTC Therapeutics announced that the Proceedings of the National Academy of Sciences (PNAS) has published new results further validating Translarna's™ (ataluren) mechanism of action to promote readthrough of premature stop codons resulting from nonsense mutations in…

Continue

Added by PPMD on October 4, 2016 at 11:00am — No Comments


Staff
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

Today, Sarepta Therapeutics and Summit announced a license and collaboration agreement, which grants Sarepta the right to commercialize Summit's utrophin modulators in Europe should they receive approval. This includes ezutromid, which is currently in the Phase 2…

Continue

Added by PPMD on October 4, 2016 at 8:30am — No Comments


Staff
Catabasis Pharmaceuticals & Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne

PPMD is thrilled to learn of the collaboration of Catabasis and Sarepta Therapeutics, two partners deeply committed to this community. This joint research collaboration will…

Continue

Added by PPMD on September 29, 2016 at 9:21am — No Comments


Staff
Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 & SRP-4053

Sarepta Therapeutics today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping.

Read the announcement from Sarepta:…

Continue

Added by PPMD on September 28, 2016 at 6:30pm — No Comments


Staff
Santhera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Using Glucocorticoids

Santhera Pharmaceuticals today announced that the first patient has been enrolled in Santhera's phase III (SIDEROS) trial. The Phase III SIDEROS trial is designed to confirm the efficacy of Raxone in patients…

Continue

Added by PPMD on September 28, 2016 at 8:54am — No Comments


Staff
Summit Receives Fast Track Designation from FDA for Ezutromid in the Treatment of Duchenne

Summit Therapeutics plc today announced it has received Fast Track designation from the US Food and Drug Administration (FDA) for ezutromid in the treatment of…

Continue

Added by PPMD on September 26, 2016 at 9:30am — 1 Comment


Staff
Hillsdale College Announces Scholarship to Honor Ryan Newbanks

Hillsdale College announced the creation of a merit-based scholarship to honor the late Ryan Newbanks, a young man who became close to the football program while battling Duchenne muscular dystrophy. The scholarship announcement coincides with the one-year anniversary of Newbanks’ death in 2015, and also with…

Continue

Added by PPMD on September 20, 2016 at 9:00am — No Comments

Monthly Archives

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

© 2017   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service